Andrew Schiff

Dr. Andrew Schiff joined Aisling Capital in September 1999 and currently serves as one of the Managing Partners. Prior to Aisling Capital, Dr. Schiff practiced internal medicine for six years at The New York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff currently serves as a director of ARMGO Pharma, Monte Rosa therapeutics and aclaris therapeutics. He is a longtime supporter and board member of the Visiting Nurse Service of New York and the Academy of American Poets. Dr. Schiff received his MD from Cornell University Medical College, his MBA from Columbia University, and his BS with honors in neuroscience from Brown University.